Stock Analysis
Hangzhou Biotest BiotechLtd Third Quarter 2024 Earnings: EPS: CN¥0.16 (vs CN¥0.28 in 3Q 2023)
Hangzhou Biotest BiotechLtd (SHSE:688767) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥121.6m (up 21% from 3Q 2023).
- Net income: CN¥17.0m (down 43% from 3Q 2023).
- Profit margin: 14% (down from 30% in 3Q 2023). The decrease in margin was driven by higher expenses.
- EPS: CN¥0.16 (down from CN¥0.28 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hangzhou Biotest BiotechLtd's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 3 warning signs we've spotted with Hangzhou Biotest BiotechLtd (including 2 which are a bit concerning).
Valuation is complex, but we're here to simplify it.
Discover if Hangzhou Biotest BiotechLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:688767
Hangzhou Biotest BiotechLtd
Engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally.